Who Decides? The MHRA and NICE, Explained Simply?

Two bodies shape which GLP-1s you can get, and when. Here's what each one does, in plain English.

Key takeaways

• The MHRA decides whether a medicine is safe and licenses it.
• NICE decides who the NHS should offer it to, and when.
• They answer two different questions.
• Both protect patients, in different ways.

When people ask 'why can't I just get this?', the answer usually involves two organisations with similar-sounding names. They're easy to mix up, but they do quite different jobs — and once you can tell them apart, a lot of the confusion around access simply melts away.

Here's the short version before the detail: one body decides whether a medicine is allowed in the UK at all, and the other decides whether the NHS should pay for it and for whom. A medicine can clear the first hurdle yet still face the second. Both exist to look after patients — just from different angles.

The MHRA: is it safe, and does it work?

The Medicines and Healthcare products Regulatory Agency licenses medicines for use in the UK. It assesses each one for safety, quality and effectiveness, and defines exactly what it's approved to treat — its licensed indication. Without an MHRA licence, a medicine can't be marketed here at all.

The MHRA's work doesn't stop at approval. It keeps watching a medicine once it's in use, gathering reports of side effects and stepping in if new safety concerns emerge — through its long-running scheme for reporting suspected reactions. So its role is really a continuous one: is this medicine safe and effective, today and over time?

NICE: should the NHS provide it, and to whom?

The National Institute for Health and Care Excellence answers a different question. Once a medicine is licensed, NICE weighs up the evidence — including how well it works and whether it represents good value — and advises which treatments the NHS should fund, and the criteria for who should receive them.

This is why two people can both have a licensed medicine in front of them, yet only one is offered it on the NHS. NICE's recommendations are what shape those eligibility rules — the thresholds and conditions that decide who qualifies.

Two questions, two answers

The simple split MHRA asks: is this medicine safe and effective, so should it be allowed? NICE asks: should the NHS offer it, and to whom? A medicine can be fully licensed and still carry NHS eligibility rules.

A helpful way to picture it: the MHRA opens the door to the UK, and NICE decides which of those medicines the NHS will stock on its shelves and hand out, and to which patients. Neither is a barrier for its own sake — both are forms of protection, one for safety and one for fair, evidence-based use of shared resources.

What this means for you

If you've been told a GLP-1 is 'licensed' but you still can't get it on the NHS, you're not misunderstanding anything — that's the system working exactly as designed. The licence and the funding decision are separate steps. It also explains why a private clinic can lawfully prescribe a licensed medicine that the NHS may not offer you, since the NICE funding question doesn't apply in the same way privately.

To see how the NICE side plays out in practice, read Getting a GLP-1 on the NHS. And for a real-world example of these rules in action, Shortages and Supply shows how guidance can steer which patients get priority when stock is tight.

Sources

• MHRA
• NICE
• NHS